Riskpilot← Back to searchSign inGet full accessFORWARD PHARMA A/S
A/SIn liquidationCVR 28865880Strandvejen 125Research and experimental development on natural sciences and engineering · NACE 7210Est. 20052 employees
Revenue 2024
DKK -9,5M
+54% vs 2023
EBITDA margin
119.4%
-42% vs 2023
Equity ratio
58.5%
Financial strength
Net profit 2024
DKK 75,9M
+2081% vs 2023
| Revenue | DKK -9,5M | +54% |
| EBITDA | DKK -11,3M | -42% |
| Net profit | DKK 75,9M | +2081% |
| Total assets | DKK 835,4M | +19% |
| Equity | DKK 488,3M | +15% |
| Employees | 2 | — |
Legal name
FORWARD PHARMA A/S
CVR number
28865880
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 2005
Share capital
DKK 1.014.736
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Strandvejen 125
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -10.967 | — | — | — | 1.250.000 | 0 | -5.969 | -7.764 | -10.813 | -11.632 | -6.131 | -9.458 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -39.071 | -16.080 | -5.055 | -2.877 | -3.074 | -1.827 | -1.838 |
| EBITDA | -10.967 | -9.849 | -23.310 | -40.308 | 1.136.779 | -65.666 | -31.454 | -24.321 | -24.879 | -43.890 | -7.958 | -11.296 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -10.967 | -9.849 | -23.310 | -40.308 | 1.136.779 | -65.666 | -31.454 | -24.321 | -24.879 | -43.890 | -7.958 | -11.296 |
| Net financials | 33.368 | 436 | 12.284 | 1.116 | -3.847 | 9.438 | 2.989 | -17.882 | 12.608 | 12.407 | 4.125 | 1.364 |
| Profit before tax | 22.401 | -13.912 | -51.401 | -9.384 | 1.132.932 | -56.228 | -28.465 | -42.203 | -12.271 | -31.483 | -3.833 | -9.932 |
| Tax | -0 | -250 | -336 | -11.416 | 252.722 | -1.933 | -0 | -1 | -0 | -0 | -0 | -85.859 |
| Net profit | 22.401 | -13.662 | -51.065 | 2.032 | 880.210 | -54.295 | -28.465 | -42.202 | -12.271 | -31.483 | -3.833 | 75.928 |
| Item | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 64.948 | 240.310 | 179.933 | 199.203 | 173.810 | 539.859 | 613.146 | 574.866 | 561.060 | 529.878 | 704.685 | 835.352 |
| Equity | 50.424 | 238.017 | 176.695 | 189.657 | 89.390 | 534.576 | 515.927 | 474.107 | 461.863 | 430.397 | 426.446 | 488.330 |
| Long-term debt | 11.882 | 0 | 0 | 0 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.642 | 2.293 | 3.238 | 9.546 | 84.380 | 5.284 | 97.219 | 100.759 | 99.197 | 99.482 | 278.239 | 347.022 |
| Total debt | 14.524 | 2.293 | 3.238 | 9.546 | 84.420 | 5.284 | 97.219 | 100.759 | 99.197 | 99.482 | 278.239 | 347.022 |
EBITDA margin
-1129603600.0%
This company
15.8%
Market median
-7149389973% vs market
20122024
Equity ratio
58.5%
This company
38.2%
Market median
+53% vs market
20122024
Return on equity
15.5%
This company
18.4%
Market median
+16% vs market
20122024
Net profit margin
7592764500.0%
This company
8.1%
Market median
+93737833233% vs market
20122024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Management | Management | 2012 | — | — |
LF Management | Management | 2006 | — | — |
CB Management | Management | 2017 | — | — |
JD Management | Management | 2014 | — | — |
MP Management | Management | 2010 | — | — |
RS Management | Management | 2016 | — | — |
JD Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2012 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2024 | |
NORDIC BIOTECH OPPORTUNITY FUND K/S | Company | 20.0% | 20.0% | 2024 |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 20.0% | 20.0% | 2014 | |
| Individual | 10.0% | 10.0% | 2024 | |
NORDIC BIOTECH K/S | Company | 20.0% | 20.0% | 2024 |
NB FP INVESTMENT K/S | Company | 5.0% | 5.0% | 2014 |
| Individual | 15.0% | 15.0% | 2014 | |
FORWARD PHARMA A/S | Company | 5.0% | 5.0% | 2024 |
| Individual | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FORWARD PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peder Møller Andersen | Management | 0 companies |
| Lars Folke Henrik Nilsson | Management | 0 companies |
| Claus Bo Søndergaard Svendsen | Management | 0 companies |
| Joel David Sendek | Management | 0 companies |
| Morten Priskorn | Management | 0 companies |
| Rupert Sandbrink | Management | 0 companies |
| Joel David Sendek | Management | 0 companies |
| Duncan Moore | Board of Directors | 0 companies |
| Wyle David Solomon | Chairman | 0 companies |
| Grant Hellier Lawrence | Board of Directors | 0 companies |
| Johannes Gerardus Joseph van de Winkel | Board of Directors | 0 companies |
| Hans Thalsgård Schambye | Board of Directors | 0 companies |
| Marianne Kock | Board of Directors | 0 companies |
| Christian Karsten Hansen | Board of Directors | 0 companies |
| Jakob Mosegaard Larsen | Board of Directors | 0 companies |
| Karen Lesley Smith | Board of Directors | 0 companies |
| John Kevin Buchi | Board of Directors | 0 companies |
| Florian Schønharting | Chairman | 0 companies |
| Torsten Goesch | Board of Directors | 0 companies |